CPRX | Catalyst Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	19.26 - 19.94
52 Week Range	11.55 - 20.87
Beta	0.68
Implied Volatility	40.80%
IV Rank	29.36%
Day's Volume	711,112
Average Volume	1,100,298
Shares Outstanding	118,688,000
Market Cap	2,326,284,800
Sector	Healthcare
Industry	Biotechnology
IPO Date	2006-11-08

Valuation
Profitability
Growth
Health
P/E Ratio	35.00
Forward P/E Ratio	14.81
EPS	0.56
1YR Price Target	12.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	167
Country	USA
Website	CPRX

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

CPRX's peers: DAWN, TERN, XFOR, INZY, MREO, EXEL, TGTX, VKTX, MDGL, BTAI, AXSM, INCY, IMGN, SRPT, ACAD, ICPT, HEPA, AKRO, RETA

*Chart delayed

Analyzing fundamentals for CPRX we got that it has strong fundamentals where Valuation is considered to be fairly valued, Profitability is very wealthy, Growth is exceptionally good and Health is confidently strong. For more detailed analysis please see CPRX Fundamentals page.

Watching at CPRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CPRX Technicals page.